Expert Review of Clinical Immunology最新文献_第10页

The CXCLs-CXCR2 axis modulates the cross-communication between tumor-associated neutrophils and tumor cells in cervical cancer. CXCLs-CXCR2 轴调节宫颈癌中肿瘤相关中性粒细胞与肿瘤细胞之间的交叉通讯。

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-05-01 Epub Date: 2024-01-24 DOI: 10.1080/1744666X.2024.2305808

Hai-Zhou Ji, Bin Liu, Mi Ren, Sang Li, Jian-Feng Zheng, Tong-Yu Liu, Hui-Hui Yu, Yang Sun

{"title":"The CXCLs-CXCR2 axis modulates the cross-communication between tumor-associated neutrophils and tumor cells in cervical cancer.","authors":"Hai-Zhou Ji, Bin Liu, Mi Ren, Sang Li, Jian-Feng Zheng, Tong-Yu Liu, Hui-Hui Yu, Yang Sun","doi":"10.1080/1744666X.2024.2305808","DOIUrl":"10.1080/1744666X.2024.2305808","url":null,"abstract":"Objective: This study aimed to check the expression profile of the C-X-C motif chemokine ligands (CXCLs)-C-X-C motif chemokine receptor 2 (CXCR2) axis in cervical cancer and to explore the cross-talk between cervical cancer cells and neutrophils via CXCLs-CXCR2 axis.Methods: Available RNA-sequencing data based on bulk tissues and single-cell/nucleus RNA-sequencing data were used for bioinformatic analysis. Cervical cancer cell lines Hela and SiHa cells were utilized for in vitro and in vivo studies.Results: Except for neutrophils, CXCR2 mRNA expression is limited in other types of cells in the cervical tumor microenvironment. CXCLs bind to CXCR2 and are mainly expressed by tumor cells. CXCL1, 2, 3, 5, 6, and 8, which are consistently associated with neutrophil infiltration, are also linked to poor prognosis. SB225002 (a CXCR2 inhibitor) treatment significantly impairs SiHa cell-induced neutrophil migration. CXCL1, CXCL2, CXCL5, or CXCL8 neutralized conditioned medium from SiHa cells have weaker recruiting effects. The conditioned medium of neutrophils from healthy donors can slow cancer cell proliferation. Conditioned medium of tumor-associated neutrophils (TANs) can drastically enhance cervical cancer cell growth in vitro and in vivo.Conclusions: The CXCLs-CXCR2 axis is critical in neutrophil recruitment and tumor cell proliferation in the cervical cancer microenvironment.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"559-569"},"PeriodicalIF":4.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Why does malaise/fatigue occur? Underlying mechanisms and potential relevance to treatments in rheumatoid arthritis. 为什么会出现乏力/疲劳？类风湿性关节炎的潜在治疗机制和相关性。

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-05-01 Epub Date: 2024-01-19 DOI: 10.1080/1744666X.2024.2306220

Yoshiya Tanaka, Kei Ikeda, Yuko Kaneko, Naoki Ishiguro, Tsutomu Takeuchi

{"title":"Why does malaise/fatigue occur? Underlying mechanisms and potential relevance to treatments in rheumatoid arthritis.","authors":"Yoshiya Tanaka, Kei Ikeda, Yuko Kaneko, Naoki Ishiguro, Tsutomu Takeuchi","doi":"10.1080/1744666X.2024.2306220","DOIUrl":"10.1080/1744666X.2024.2306220","url":null,"abstract":"Introduction: Fatigue and malaise are commonly associated with a wide range of medical conditions, including rheumatoid arthritis (RA). Evidence suggests that fatigue and malaise can be overwhelming for patients, yet these symptoms remain inadequately-managed, largely due to an incomplete elucidation of the underlying causes.Areas covered: In this assessment of the published literature relating to the pathogenesis of fatigue or malaise in chronic conditions, four key mechanistic themes were identified. Each theme (inflammation, hypothalamic-pituitary-adrenal axis, dysautonomia, and monoamines) is discussed, as well as the complex network of interconnections between themes which suggests a key role for inflammatory cytokines in the development and persistence of fatigue.Expert opinion: Fatigue is multifaceted, poorly defined, and imperfectly comprehended. Moreover, the cause and severity of fatigue may change over time, as a consequence of the natural disease course or pharmacologic treatment. This detailed synthesis of available evidence permits us to identify avenues for current treatment optimization and future research, to improve the management of fatigue and malaise in RA. Within the development pipeline, several new anti-inflammatory therapies are currently under investigation, and we anticipate that the next five years will herald much-needed progress to reduce the debilitating nature of fatigue in patients with RA.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"485-499"},"PeriodicalIF":4.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm. 治疗化脓性扁桃体炎的生物制剂：治疗模式的演变。

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-05-01 Epub Date: 2024-01-02 DOI: 10.1080/1744666X.2023.2298356

Carlo Alberto Maronese, Chiara Moltrasio, Giovanni Genovese, Angelo Valerio Marzano

{"title":"Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm.","authors":"Carlo Alberto Maronese, Chiara Moltrasio, Giovanni Genovese, Angelo Valerio Marzano","doi":"10.1080/1744666X.2023.2298356","DOIUrl":"10.1080/1744666X.2023.2298356","url":null,"abstract":"Introduction: Hidradenitis suppurativa (HS) is an autoinflammatory skin disease with a high unmet need for effective medical management. Clinically, it is characterized by inflammatory nodules that may progress into abscesses, draining tunnels and extensive scarring, mainly affecting apocrine gland-bearing areas.Areas covered: Treatment options include topical and systemic medications and a variety of surgical procedures. The anti-TNF-α antibody adalimumab and the anti-IL-17 secukinumab are the only two approved biologics for HS, showing moderate efficacy. HS research is a rapidly growing field, with a wide range of agents leveraging distinct mechanisms of action currently under development. Drugs targeting the IL-17 and Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathways are the most advanced in both ongoing and completed Phase 3 studies, promising deeper levels of response. Use of other, off-label biologics is also discussed.Expert opinion: A therapeutic algorithm is proposed based on comorbidities and existing evidence. Patient-tailored combinations between biologics and other biologics or small molecules will hopefully allow clinicians to target most events in HS pathophysiology in a complementary way while obtaining a meaningful effect on their devastating manifestations.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"525-545"},"PeriodicalIF":4.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138828998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The clinical role of anakinra in the armamentarium against familial Mediterranean fever. Anakinra 在防治家族性地中海热武器库中的临床作用。

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-05-01 Epub Date: 2023-12-30 DOI: 10.1080/1744666X.2023.2299230

Kerem Parlar, Muhammed Bahaddin Ates, Bugra Han Egeli, Serdal Ugurlu

{"title":"The clinical role of anakinra in the armamentarium against familial Mediterranean fever.","authors":"Kerem Parlar, Muhammed Bahaddin Ates, Bugra Han Egeli, Serdal Ugurlu","doi":"10.1080/1744666X.2023.2299230","DOIUrl":"10.1080/1744666X.2023.2299230","url":null,"abstract":"Introduction: Familial Mediterranean Fever (FMF) is the most common autoinflammatory disease that has mainly been treated with colchicine since 1972. A significant portion of patients do not respond to colchicine and require further treatment, mainly IL-1β antagonists such as anakinra, canakinumab and rilonacept as IL-1β has a crucial role in pathogenesis of FMF. This review summarizes the current approach to treating FMF and discovers the pharmacological and clinical utility of IL-1 blocking agents based on accumulated evidence with a focus on anakinra.Areas covered: This review focuses on anakinra treatment in FMF. The data obtained from case reports, case series, retrospective studies and a Phase III trial are analyzed. Safety and efficacy profiles of anakinra are discussed.Expert opinion: Anakinra is the cheapest anti-IL-1 agent used in the treatment of colchicine-resistant FMF. It is shown to be effective and safe when used in adjunct to colchicine however its short half-life and potential to cause injection site reactions limit its use.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"441-453"},"PeriodicalIF":4.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Upadacitinib for the treatment of adult patients with active psoriatic arthritis. 用于治疗活动性银屑病关节炎成年患者的奥帕他替尼。

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-05-01 Epub Date: 2023-12-28 DOI: 10.1080/1744666X.2023.2299732

Antonio Marchesoni, Giorgia Citriniti, Nicolò Girolimetto, Niccolò Possemato, Carlo Salvarani

{"title":"Upadacitinib for the treatment of adult patients with active psoriatic arthritis.","authors":"Antonio Marchesoni, Giorgia Citriniti, Nicolò Girolimetto, Niccolò Possemato, Carlo Salvarani","doi":"10.1080/1744666X.2023.2299732","DOIUrl":"10.1080/1744666X.2023.2299732","url":null,"abstract":"Introduction: Psoriatic arthritis (PsA) is a rheumatic disorder that may be responsible for relevant articular impairment. The recently licensed Janus Kinase (JaK) inhibitors represent a new opportunity to improve PsA treatment. This review deals with the clinical usefulness of the selective JaK-1 inhibitor upadacitinib (UPA) in patients with PsA.Covered areas: Two phase-III studies are available: SELECT-PsA 1, performed in patients with an inadequate response to non-biological therapies, and SELECT-PsA 2, conducted in biologic-experienced patients. Long-term extension results and post-hoc analysis data of these two trials are also available.Expert opinion: The results provided by the trials indicate that UPA may be used to treat all of the clinical manifestations of PsA. Venous thromboembolism, cardiovascular events, and malignancy, the most feared adverse events associated with JaK inhibitor use, were not increased in the trial populations, yet long-term observational studies are needed to make sure that UPA is safe in this respect.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"423-434"},"PeriodicalIF":4.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139058264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Considerations for managing elderly patients with atopic dermatitis. 管理老年特应性皮炎患者的注意事项。

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-05-01 Epub Date: 2024-01-09 DOI: 10.1080/1744666X.2024.2301967

Maddalena Napolitano, Luca Potestio, Mariateresa Nocerino, Cataldo Patruno

{"title":"Considerations for managing elderly patients with atopic dermatitis.","authors":"Maddalena Napolitano, Luca Potestio, Mariateresa Nocerino, Cataldo Patruno","doi":"10.1080/1744666X.2024.2301967","DOIUrl":"10.1080/1744666X.2024.2301967","url":null,"abstract":"Introduction: Atopic dermatitis (AD) diagnosis in elderly is challenging, due to its clinical polymorphism and the lack of diagnostic biomarkers. Moreover, the chronicity of the disease and the complex pathogenetic mechanism, make elderly AD management challenging.Areas covered: A narrative review of the current literature was performed using the PubMed, Medline, Embase, and Cochrane Skin databases, by researching the following terms: 'atopic dermatitis,' 'clinical phenotypes,' 'eczema,' 'elderly patients,' 'elderly type atopic dermatitis,' 'eczema clinical presentation.' The aim was to report the current knowledge on pathogenesis, clinical presentation, and treatment options of elderly AD.Expert opinion: Elderly type AD has recently been identified as a separate entity, with an increasing prevalence. With aging, both immunosenescence and barrier alterations can cause or modify AD presentation. Moreover, a chronic proinflammatory state (so-called 'inflammaging') is often present in elderly subjects. Older patients with AD may present with peculiar immunophenotypic profile, making AD diagnosis challenging. Similarly, the chronicity of the disease and the complex pathogenetic mechanism, make AD management a challenge. Indeed, systemic therapies for AD are often contraindicated or not tolerated and the management of elderly type AD is often burdened with numerous difficulties, leading to undertreated disease. Even if dupilumab and tralokinumab represent a valuable therapeutic weapon, more data on safety of JAK inhibitors are required.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"501-511"},"PeriodicalIF":4.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Matrix metalloproteinases in chronic rhinosinusitis. 慢性鼻炎中的基质金属蛋白酶

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-05-01 Epub Date: 2024-01-22 DOI: 10.1080/1744666X.2024.2302362

Yuqing Huang, Bing Yan, Chen Meng, Luo Zhang, Chengshuo Wang

{"title":"Matrix metalloproteinases in chronic rhinosinusitis.","authors":"Yuqing Huang, Bing Yan, Chen Meng, Luo Zhang, Chengshuo Wang","doi":"10.1080/1744666X.2024.2302362","DOIUrl":"10.1080/1744666X.2024.2302362","url":null,"abstract":"Introduction: Matrix metalloproteinases (MMPs) are a group of enzymes that are essential in maintaining extracellular matrix (ECM) homeostasis, regulating inflammation and tissue remodeling. In chronic rhinosinusitis (CRS), the overexpression of certain MMPs can contribute to chronic nasal tissue inflammation, ECM remodeling, and tissue repair.Areas covered: This review provides a comprehensive overview of the biological characteristics and functions of the MMP family, particularly focusing on the expression and activity of MMPs in patients with CRS, and delves into their role in the pathogenesis of CRS and their potential as therapeutic targets.Expert opinion: MMPs are important in tissue remodeling and have been implicated in the pathophysiology of CRS. Previous studies have shown that the expression of MMPs is upregulated in the nasal mucosa of patients with CRS and positively correlates with the severity of CRS. However, there is still a large gap in the research content of MMP in CRS, and the specific expression and pathogenic mechanism of MMP still need to be clarified. The significance and value of the ratio of MMP to tissue inhibitors of metalloproteinase (TIMP) in diseases still need to be demonstrated. Moreover, further studies are needed to assess the efficacy and safety of biologics that target MMPs in patients with CRS.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"547-558"},"PeriodicalIF":4.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139511985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Discoveries in the genetics and genomics of systemic juvenile idiopathic arthritis 系统性幼年特发性关节炎遗传学和基因组学的新发现

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-04-20 DOI: 10.1080/1744666x.2024.2345868

Mariana Correia Marques, Michael J. Ombrello, Grant S. Schulert

引用次数: 0

Basophil activation test in the food allergy clinic: its use current use and future applications 食物过敏门诊中的嗜碱性粒细胞活化测试：当前使用情况和未来应用

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-04-09 DOI: 10.1080/1744666x.2024.2336568

Marcel M. Bergmann, Alexandra F. Santos

引用次数: 0

Neuro-ophthalmic challenges and multi-morbidity in vasculitis among the older adults 老年人脉管炎的神经眼科挑战和多病症问题

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-04-04 DOI: 10.1080/1744666x.2024.2339893

Caezaan Keshvani, Noor Laylani, Pamela Davila-Siliezar, Jonathan Kopel, Andrew G Lee

引用次数: 0